The ripple effects of GLP-1s
SIOUX FALLS, S.D. (Dakota News Now) – Weight-loss medications are making headlines nationwide, but their impact may be…
What a Nutritionist Would Eat in a Day on GLP-1s for Protein, Fiber
Since GLP-1s for weight loss hit the scene a few years ago, Rob Hobson, a nutritionist, has been…
GLP-1 Patients Report New Side Effect—and It’s Hitting Relationships Hard
(c)jonchallicom.com/Getty Images Move over, “Ozempic itch.” A new side effect is raising alarm among experts, and it goes…
Our Piece Should Have Included That Information
Sign up to see the future, today Can’t-miss innovations from the bleeding edge of science and tech Last…
Ozempic, GLP-1 drugs may lead to divorce boom, experts warn
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our…
6 drugs invented for one thing — but now treat another
Just think, we may have never gotten the “Oh, oh, oh, Ozempic!” jingle stuck in our heads if…
Surge of generic weight-loss drugs triggers price war in India
Open this photo in gallery: Obesity doctor and consultant Swati Pradhan explains the Mounjaro GLP-1 self-injectable device at…
All about new ‘triple-G’ drug that’s helped patients lose a quarter of their body weight
G whiz! The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight…
Large GLP-1 Drug Review Takes Closer Look at Risks, Rewards
Moderate- to high-quality evidence from an umbrella review on non-cardiometabolic outcomes reinforced links between GLP-1 therapies and risks…
Lilly’s weight-loss pill wins FDA approval
For the first time, regulators have approved a small-molecule pill targeting glucagon-like peptide1 (GLP-1) for weight loss.…
FDA Approves Eli Lilly’s GLP-1 Pill
The US Food and Drug Administration on Wednesday approved a new obesity pill called Foundayo. Taken once daily,…
GLP-1 drugs reshape alcohol consumption and hospitality habits
Millions of Britons using GLP-1 weight loss medications are beginning to alter how they drink, dine and choose…